Pharmaceutical Industry Reports Acne Vulgaris Treatment Market | Page 2

REPORT DESCRIPTION
Acne Vulgaris Treatment Market – Overview
According to a study published in the British Journal of Dermatology in 2015, 9.4% of global population was estimated
to be affected by acne. Moreover, globally, acne is the eight most prevalent disease. The U.S. is the largest market for
acne vulgaris treatment products. According to study by National Institute of Health (NIH), in 2013, over US$ 3 Billion
was spent for treating acne vulgaris in the U.S. In 2014, according to American Academy of Dermatology, the number of
acne vulgaris patient aged 25 years and above, especially women, is rising significantly. Furthermore, low awareness
regarding the factors causing acne is another factor leading to increasing prevalence acne vulgaris.
Treatment for acne on an average lasts for two years, therefore companies capitalize on this and earn sustainable revenue
from acne treatment products. Majority of the population suffering from acne prefer OTC products as first line therapy.
However, some have to visit dermatologist to cure acne vulgaris on account of ineffective result from OTC products.
Acne vulgaris is a common skin disease characterized by blackheads, whiteheads, papules, and pustules on the face, neck,
back, and chest. It is commonly observed in adolescent population, however, can also affect adults. Depending on its
severity, acne may be segmented into mild, moderate or severe. It is caused due to excess oil produced in sebaceous
glands under skin, which becomes plugged and inflated.